XML 18 R3.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Balance Sheets (Parentheticals) - USD ($)
$ / shares in Thousands, $ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Unrestricted cash and cash equivalents $ 375,416 $ 339,338
Restricted cash and cash equivalents 124,220 44,315
Loans, interest and fees receivable, at fair value 2,630,274 2,173,759
Allowance for credit losses 4,900 1,800
Deferred revenue 19,800 17,900
Notes payable, at face value $ 2,199,448 $ 1,861,685
Common stock, par value (in dollars per share) $ 0 $ 0
Common stock, authorized (in shares) 150,000,000 150,000,000
Common stock, issued (in shares) 14,904,192 14,603,563
Common stock, outstanding (in shares) 14,904,192 14,603,563
Series A Preferred Stock [Member]    
Preferred stock, shares authorized (in shares) 10,000,000 10,000,000
Preferred stock, shares issued (in shares) 400,000 400,000
Preferred stock, shares outstanding (in shares) 400,000 400,000
Preferred stock, liquidation preference $ 40,000 $ 40,000
Series B Preferred Stock [Member]    
Preferred stock, no par value (in dollars per share) $ 0 $ 0
Preferred stock, shares issued (in shares) 3,301,179 3,256,561
Preferred stock, shares outstanding (in shares) 3,301,179 3,256,561
Preferred stock, liquidation preference $ 82,500 $ 81,400
Variable Interest Entity, Primary Beneficiary [Member]    
Unrestricted cash and cash equivalents 140,200 158,000
Restricted cash and cash equivalents 98,800 20,500
Loans, interest and fees receivable, at fair value 2,542,900 2,128,600
Notes payable, at face value $ 2,128,000 $ 1,795,900